Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2020 2458
2021 1559
Text availability
Article attribute
Article type
Publication date

Search Results

3,715 results
Results by year
Filters applied: . Clear all
Page 1
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
Ferrara F, Vitiello A. Ferrara F, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun 21. doi: 10.1007/s00210-021-02108-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34151392
In March 2019, the global COVID-19 pandemic caused by the novel SARS-CoV-2 coronavirus began. The first cases of SARS-CoV-2 infection occurred in November 19 in Wuhan, China. Preventive measures taken ha …
In March 2019, the global COVID-19 pandemic caused by the novel SARS-CoV-2 coronavirus bega …
Cardiovascular and renal risk factors and complications associated with COVID-19.
Touyz RM, Boyd MO, Guzik T, Padmanabhan S, McCallum L, Delles C, Mark PB, Petrie JR, Rios F, Montezano AC, Sykes R, Berry C. Touyz RM, et al. CJC Open. 2021 Jun 16. doi: 10.1016/j.cjco.2021.05.020. Online ahead of print. CJC Open. 2021. PMID: 34151246 Free PMC article. Review.
The current COVID-19 pandemic, caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome-Coronavirus-2), represents the largest medical challenge in decades. ...Specifically ACE2, a multifunctional protein of the RAS …
The current COVID-19 pandemic, caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome- …
Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.
Emon NU, Alam MM, Akter I, Akhter S, Sneha AA, Irtiza M, Afroj M, Munni A, Chowdhury MH, Hossain S. Emon NU, et al. Futur J Pharm Sci. 2021;7(1):121. doi: 10.1186/s43094-021-00275-7. Epub 2021 Jun 15. Futur J Pharm Sci. 2021. PMID: 34150913 Free PMC article.
BACKGROUND: COVID-19 has mutation capability, and there are no specific drug therapies that are available to fight or inhibit the proteins of this virus. ...CONCLUSION: Therefore, the selected compounds could be considered a potential herbal treatment source …
BACKGROUND: COVID-19 has mutation capability, and there are no specific drug therapies that are available to fight or inhibit …
Surface adhesion of viruses and bacteria: Defend only and/or vibrationally extinguish also?! A perspective.
Kolel-Veetil M, Sen A, Buehler MJ. Kolel-Veetil M, et al. MRS Adv. 2021 Jun 15:1-7. doi: 10.1557/s43580-021-00079-0. Online ahead of print. MRS Adv. 2021. PMID: 34150335 Free PMC article.
Coronaviruses COVID-19, SARS-CoV and NL63 use spikes in their corona to bind to angiotensin converting enzyme 2 (ACE2) sites on cytoskeletal membranes of host cells to deliver their viral payload. While groups such as disulfides in …
Coronaviruses COVID-19, SARS-CoV and NL63 use spikes in their corona to bind to angiotensin conver …
Expression of SARS-CoV-2 entry genes ACE2 and TMPRSS2 at single cell resolution in the peripartum decidua.
Li Q, Wang W, Pei C, Zhao Y, Liu R, Zhang W, Huang L, Li T, Huang J. Li Q, et al. Am J Transl Res. 2021 May 15;13(5):4389-4400. eCollection 2021. Am J Transl Res. 2021. PMID: 34150021 Free PMC article.
Angiotensin-converting enzyme 2 (ACE2) is the key receptor for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). ...After labor onset, the upregulated genes changed to include cell junction assembly genes. The susceptib
Angiotensin-converting enzyme 2 (ACE2) is the key receptor for severe acute respiratory syndrome-coronavirus-2 (
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Deshpande A, et al. Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021. Front Immunol. 2021. PMID: 34149735 Free PMC article.
Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID19) that is responsible for short and long-term disease, as well as death, in susceptible hosts. ...The analysis also identified a no …
Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (CO
SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage.
Sui Y, Li J, Venzon DJ, Berzofsky JA. Sui Y, et al. Front Immunol. 2021 Jun 4;12:658428. doi: 10.3389/fimmu.2021.658428. eCollection 2021. Front Immunol. 2021. PMID: 34149696 Free PMC article.
SARS-CoV-2 virus causes upper and lower respiratory diseases including pneumonia, and in some cases, leads to lethal pulmonary failure. Angiotensin converting enzyme-2 (ACE2), the receptor for cellular entry of SARS-CoV-2
SARS-CoV-2 virus causes upper and lower respiratory diseases including pneumonia, and in some cases, leads to le
Rational optimization of a human neutralizing antibody of SARS-CoV-2.
Chen J, Wu F, Lin D, Kong W, Cai X, Yang J, Sun X, Cao P. Chen J, et al. Comput Biol Med. 2021 Jun 12;135:104550. doi: 10.1016/j.compbiomed.2021.104550. Online ahead of print. Comput Biol Med. 2021. PMID: 34147856
SARS-CoV-2 has caused a worldwide epidemic of coronavirus disease 19 (COVID-19). Antibody drugs present an effective weapon for tens of millions of COVID-19 patients. Antibodies disrupting the interactions between the
SARS-CoV-2 has caused a worldwide epidemic of coronavirus disease 19 (COVID-19). Antibody d
Covid-19 pandemic: Perspectives on management.
Gathiram P, Moodley J, Khaliq OP. Gathiram P, et al. J Reprod Immunol. 2021 Jun 5;146:103344. doi: 10.1016/j.jri.2021.103344. Online ahead of print. J Reprod Immunol. 2021. PMID: 34146892 Review.
The pandemic COVID-19 presents a major challenge to identify effective drugs for treatment. ...Adequately powered randomized trials are required for drugs with in vitro activity against the virus. Supportive care should be provided for stable, hypoxia and pne …
The pandemic COVID-19 presents a major challenge to identify effective drugs for treatment. ...Adequately powered randomized t …
TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2.
Wang Y, Fan Y, Huang Y, Du T, Liu Z, Huang D, Wang Y, Wang N, Zhang P. Wang Y, et al. Cell Signal. 2021 Jun 16:110064. doi: 10.1016/j.cellsig.2021.110064. Online ahead of print. Cell Signal. 2021. PMID: 34146659
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019, it binds to angiotensin-converting enzyme 2 (ACE2) to enter into human cells. ...Our study identified TRIM28 as a …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease …
3,715 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page